Small Pharma has had its second United States patent granted by the United States Patent Office.
Silo Wellness has confirmed it has acquired Dyscovry Science – a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives, targeting irritable bowel...
A wholly-owned subsidiary of HYTN Innovations Inc.,
The European Psychiatric Association (EPA) is joining the Psychedelic Access and Research European Alliance (PAREA) as a full member.
Palo Santo has announced the closing of its USD$50m (~£134.10m) fund which will go towards a diverse portfolio of businesses developing innovative psychedelic medicines and therapies.
Biomind Labs has confirmed that it has had a Pre-Investigational New Drug (Pre-IND) meeting granted by the U.S.
APPA is aiming to integrate psychedelics into the US healthcare system and ensure safe access for all who can benefit from the treatments.
UK-based global nootropics company Puresport has had its Reishi, Cordyceps and Lion’s Mane supplements certified by Informed Sport, the gold-standard independent certification body.
Psyence Group has completed an export of psilocybin to Psilo Pharma from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner...
Cybin has entered into an agreement with Mindset Pharma to acquire an exclusive license to an extensive, targeted class of tryptamine-based molecules.